Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study

Aaron S. Kesselheim (), Sarah A. McGraw, Sara Z. Dejene, Paula Rausch, Gerald J. Dal Pan, Brian M. Lappin, Esther H. Zhou, Jerry Avorn and Eric G. Campbell
Additional contact information
Aaron S. Kesselheim: Brigham and Women’s Hospital and Harvard Medical School
Sarah A. McGraw: The Hastings Center
Sara Z. Dejene: Brigham and Women’s Hospital and Harvard Medical School
Paula Rausch: Center for Drug Evaluation and Research
Gerald J. Dal Pan: Center for Drug Evaluation and Research
Brian M. Lappin: Center for Drug Evaluation and Research
Esther H. Zhou: Center for Drug Evaluation and Research
Jerry Avorn: Brigham and Women’s Hospital and Harvard Medical School
Eric G. Campbell: Massachusetts General Hospital and Harvard Medical School

Drug Safety, 2017, vol. 40, issue 6, No 9, 542 pages

Abstract: Abstract Introduction The US Food and Drug Administration uses drug safety communications (DSCs) to release emerging information regarding post-market safety issues, but it is unclear the extent of awareness by patients and providers of these communications and their specific recommendations. Objective We conducted semi-structured interviews with patients and physicians to evaluate their awareness and understanding of emerging drug safety information related to two sleep aids: zolpidem or eszopiclone. Methods We conducted interviews with 40 patients and ten physicians recruited from a combination of insurer claims databases and online sources. We evaluated (1) sources of drug safety information; (2) discussions between patients and physicians about the two medications; (3) their knowledge of the DSC; and (4) preferences for learning about future drug safety information. Interviews were transcribed and analyzed thematically. Results Patients cited their physicians, pharmacy inserts, and the Internet as sources of drug safety information. Physicians often referred to medical journals and online medical sources. Most patients reported being aware of information contained in the DSC summaries they were read. Almost all patients and physicians reported discussing side effects during patient-provider conversations, but almost no patients mentioned that physicians had communicated with them key messaging from the DSCs at issue: the risk of next-morning impairment with zolpidem and the lower recommended initial dose for women. Conclusions Some risks of medications are effectively communicated to patients and physicians; however, there is still a noticeable gap between information issued by the Food and Drug Administration and patient and physician awareness of this knowledge, as well as patients’ decisions to act on this information. Disseminators of emerging drug safety information should explore ways of providing user-friendly resources to patients and healthcare professionals that can update them on new risks in a timely manner.

Keywords: Zolpidem; Varenicline; Safety Information; Eszopiclone; Sleep Medication (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://link.springer.com/10.1007/s40264-017-0516-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:40:y:2017:i:6:d:10.1007_s40264-017-0516-3

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-017-0516-3

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().